Adaptimmune Therapeutics Stock (NASDAQ: ADAP)

Adaptimmune Therapeutics (NASDAQ:ADAP) Stock, Quote.Headers.trade-ideas

Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADAP

AILE

AIMD

ANTE

CMAX

ESPR

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

HUMA

LGMK

MMAT

NDRA

PSIG

SNOA

TNON

YMAB

Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket

Biotech

Health Care

General

GLPG

FDA approves Adaptimmune Therapeutics&#39; Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S., showed a 43% ORR and a median response duration of six months.

FDA Approves Adaptimmune Therapeutics&#39; Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade

Penny Stocks

By Michael Kim

READ THE FULL ADAP RESEARCH REPORT

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics PLC

ADAPad

Adappter Token

AdaptHealth Corp

ADAPTIVE AD SYSTEMS INC by Adaptive Ad Systems, Inc.

Adaptive Ad Systems Inc

Adaptive Alpha Opportunities ETF

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

Adaptive Core ETF

Adaptive Hedged Multi-Asset Income ETF

The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets
Adaptimmune Allo-T program to be featured at the <a href="https://api.newsfilecorp.com/redirect/ZAazNTxMy3">Biotech ShowCase</a>(TM) and the Wuxi Global Forum 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that letetresgene autoleucel (lete-cel), has been granted breakthrough therapy designation by the U.S. FDA for the treatment of patients with unresectable or metastatic myxoid/round cell liposarcoma (MRCLS) who have received prior anthracycline-based chemotherapy, are positive for HLA-A&#x2A;02:01, HLA-A&#x2A;02:05, or HLA-A&#x2A;02:06, and whose tumor expresses the NY-ESO-1 antigen.
More details about the Company's sarcoma franchise, including the lete-cel clinical program and launch progress for TECELRA&#xAE; (afamitresgene autoleucel), the Company's first commercial product and the first FDA approved engineered cell therapy for a solid tumor, will be provided during the Company's presentation at the Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, California, on Tuesday, January 14th, 2025, 4:30-5:10 PM PST (<a href="https://api.newsfilecorp.com/redirect/aramjSwMKB">Webcast access here</a>).

Guidance

Adaptimmune Reports Breakthrough Therapy Designation From FDA For Letetresgene Autoleucel In Treating MRCLS After Anthracycline Chemotherapy With 43% Response Rate; Synovial Sarcoma Shows 41% Response In Phase II Trial; Updates To Be Provided At J.P. Morgan Healthcare Conference

Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that the first patient has been treated with TECELRA&#xAE; (afamitresgene autoleucel). TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults. The patient was treated at Moffitt Cancer Center, one of Adaptimmune's Authorized Treatment Centers (ATCs) and a leader in sarcoma research and treatment.

Adaptimmune Therapeutics Announces That The First Patient Has Been Treated With TECELRA; Dosing Marks A Milestone For First Engineered Cell Therapy Approved In The U.S. For A Solid Tumor Cancer, Synovial Sarcoma

During the last three months, 4 analysts shared their evaluations of Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $2.88, along with a high estimate of $3.50 and a low estimate of $1.50. Observing a downward trend, the current average is 20.44% lower than the prior average price target of $3.62. 
<img src="https://www.benzinga.com/files/images/story/2024/1732734103_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Adaptimmune Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$1.50</td>
<td>$3.00</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.50</td>
<td>$3.50</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.50</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Adaptimmune Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Adaptimmune Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Adaptimmune Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Adaptimmune Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADAP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Adaptimmune Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Adaptimmune Therapeutics</h2>
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
<h3>Financial Milestones: Adaptimmune Therapeutics's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Adaptimmune Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 458.83%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Adaptimmune Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -43.07%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Adaptimmune Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -19.99%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Adaptimmune Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.51%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 0.93, Adaptimmune Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying Adaptimmune Therapeutics: Insights From 4 Analyst Reviews

Mizuho analyst Graig Suvannavejh maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Outperform and lowers the price target from $3 to $1.5.

Price Target

Mizuho Maintains Outperform on Adaptimmune Therapeutics, Lowers Price Target to $1.5

HC Wainwright &amp; Co. analyst Arthur He reiterates Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Buy and maintains $3.5 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Adaptimmune Therapeutics, Maintains $3.5 Price Target

Guggenheim analyst Michael Schmidt maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Buy and lowers the price target from $4 to $3.

Guggenheim Maintains Buy on Adaptimmune Therapeutics, Lowers Price Target to $3

HC Wainwright &amp; Co. analyst Arthur He maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Buy and lowers the price target from $4 to $3.5.

HC Wainwright & Co. Maintains Buy on Adaptimmune Therapeutics, Lowers Price Target to $3.5

WIIM

Adaptimmune Therapeutics shares are trading lower. The company reported Q3 financial results.

Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.13) by 46.15 percent. The company reported quarterly sales of $40.901 million which beat the analyst consensus estimate of $11.172 million by 266.09 percent. This is a 458.83 percent increase over sales of $7.319 million the same period last year.

Earnings

Earnings Beats

Adaptimmune Therapeutics Q3 2024 GAAP EPS $(0.07) Beats $(0.13) Estimate, Sales $40.901M Beat $11.172M Estimate

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 4:00:10 p.m. ET - Trading Halt: Halt News Pending

Adaptimmune To Present Data From Primary Analysis Of Phase 2 IGNYTE-ESO Trial; Says Results Include Six Complete Responses And Twenty One Partial Responses

ACXP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Adaptimmune Therapeutics to report an earnings per share (EPS) of $-0.15.
Anticipation surrounds Adaptimmune Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.32, which was followed by a 3.67% drop in the share price the next day.

<img src="https://www.benzinga.com/files/images/story/2024/1731427409_0.png" alt="eps graph" />
<h3>Performance of Adaptimmune Therapeutics Shares</h3>
Shares of Adaptimmune Therapeutics were trading at $0.8241 as of November 11. Over the last 52-week period, shares are up 60.22%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ADAP/earnings">To track all earnings releases for Adaptimmune Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of Adaptimmune Therapeutics's Earnings

Adaptimmune Therapeutics Receives Nasdaq Notice For Non-Compliance With Minimum Bid Price

HC Wainwright &amp; Co. analyst Arthur He reiterates Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Buy and maintains $4 price target.

HC Wainwright & Co. Reiterates Buy on Adaptimmune Therapeutics, Maintains $4 Price Target

Adaptimmune Therapeutics shares are trading higher. The company reported Q2 financial results.

Adaptimmune Therapeutics Q2 2024 GAAP EPS $0.04 May Not Be Comparable To $(0.08) Estimate, Sales $128.231 May Not Be Comparable To $38.483M Estimate

Shares of Ainos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) rose sharply in today's pre-market trading after the company announced that it has obtained exclusive licenses for a total of 10 invention patents and patent applications from Taiwan Carbon Nano Technology.
Ainos shares jumped 37.7% to $0.7200 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) rose 49% to $0.3201 in today's pre-market trading. On Aug. 5, LogicMark announced the closing of $4.5 million public offering priced at-the-market.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) gained 27.7% to $1.29 in pre-market trading after jumping 46% on Friday.</li>
<li>Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares rose 27.3% to $14.28 in pre-market trading.</li>
<li>FSD Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#NASDAQ">HUGE</a>) gained 24.5% to $0.2490 in pre-market trading. FSD Pharma shares jumped 118% on Friday after Celly Nutrition, which is backed by FSD Pharma, announced the upcoming launch of its &#8216;unbuzzd&#8217; recovery drink.</li>
<li>Genius Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) gained 18.5% to $0.16. Genius Group shares gained around 8% on Friday after the company announced its board approved the purchase of up to 10 million shares by founder and CEO Roger James Hamilton.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>) gained 15.4% to $1.41 in pre-market trading. The company, last week, posted a narrower-than-expected quarterly loss.</li>
<li>Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) jumped 12.8% to $1.12 in pre-market trading.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) gained 11.4% to $2.25 in pre-market trading.</li>
<li>AirNet Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) shares gained 10.1% to $0.2999 in pre-market trading after declining around 20% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Meta Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMAT#NASDAQ">MMAT</a>) shares declined 27.7% to $0.6810 in pre-market trading. Meta Materials shares dipped around 55% on Friday after the company disclosed in an SEC filing that it ceased operations and filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 in the US Bankruptcy Court.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) shares dipped 25.8% to $4.29 in pre-market trading. ILearningEngines will report financial results for the second quarter before the opening bell on Tuesday, Aug. 13.</li>
<li>Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) declined 16.9% to $0.49 in pre-market trading. Tenon Medical will release financial results for the second quarter after the closing bell on Aug. 13.</li>
<li>Sonoma Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) shares declined 15.4% to $0.21 in pre-market trading. Sonoma Pharmaceuticals shares dipped around 20% on Friday after the company reported worse-than-expected first-quarter financial results.</li>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares fell 13.4% to $6.85 in pre-market trading after the company announced that the FDA will require additional time to complete its review of the BLA for ATEV in the treatment of vascular trauma.</li>
<li>Big Tree Cloud Holdings Limited  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) shares fell 11.6% to $1.30 in pre-market trading after jumping 70% on Friday.</li>
<li>ENDRA Life Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) fell 11.1% to $0.0448 in pre-market trading. ENDRA Life Sciences will report financial results for the three and six months ended June 30 on Wednesday, Aug. 14.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) fell 7.7% to $4.19 in today's pre-market trading after the company reported worse-than-expected second-quarter results.</li>
<li>Hawaiian Electric Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) fell 7.7% to $14.28 pre-market trading after the company reported weak second-quarter earnings.</li>
<li>Pagaya Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) shares fell 6% to $13.37 in pre-market trading. The company reported second-quarter results on Friday.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/24/08/40298443/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-y"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40298443/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-y">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

In the preceding three months, 4 analysts have released ratings for Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $3.54, a high estimate of $4.00, and a low estimate of $3.00. This current average represents a 45.54% decrease from the previous average price target of $6.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1722870046_0_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Adaptimmune Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$4.00</td>
<td>-</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$3.15</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Adaptimmune Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Adaptimmune Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Adaptimmune Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Adaptimmune Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADAP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Adaptimmune Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Adaptimmune Therapeutics Better</h2>
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
<h3>Key Indicators: Adaptimmune Therapeutics's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Adaptimmune Therapeutics faced challenges, resulting in a decline of approximately -88.07% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Adaptimmune Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -854.23%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Adaptimmune Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -151.84%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Adaptimmune Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -17.94%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Adaptimmune Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.97, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Adaptimmune Therapeutics

H.C. Wainwright lowered the firm's price target on Adaptimmune (ADAP) to $3.50 from $4 and keeps a Buy rating on the shares following the Q3 report...

Adaptimmune price target lowered to $3.50 from $4 at H.C. Wainwright

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report), with a pric...

Scotiabank Remains a Buy on Adaptimmune Therapeutics (ADAP)

Wells Fargo analyst Yanan Zhu maintained a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report) yesterday and set a price target of $2....

Adaptimmune Therapeutics: Strategic Realignment and Cautious Optimism for Future Growth

Guggenheim lowered the firm's price target on Adaptimmune (ADAP) to $3 from $4 and keeps a Buy rating on the shares after the company reported Q3 r...

Adaptimmune price target lowered to $3 from $4 at Guggenheim

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Adaptimmune Therapeutics (ADAP – Research Report),...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)

Arthur He CFA, an analyst from H.C. Wainwright, maintained the Buy rating on Adaptimmune Therapeutics (ADAP – Research Report). The associated pric...

Promising Future for Adaptimmune Therapeutics: Buy Rating Supported by Breakthrough Therapies and Strong Financial Position

Leerink Partners analyst Jonathan Chang has reiterated their neutral stance on ADAP stock, giving a Hold rating on November 14. Jonathan Chang has ...

Balanced Hold Rating on Adaptimmune: Weighing Lete-cel Data and Sarcoma Market Potential

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ADAP stock, giving a Buy rating on November 19. Graig Suvannavej...

Adaptimmune Therapeutics: Strategic Restructuring and Promising Developments Drive 'Buy' Rating

Mizuho lowered the firm's price target on Adaptimmune (ADAP) to $1.50 from $3 and keeps an Outperform rating on the shares. The firm updated the co...

Adaptimmune price target lowered to $1.50 from $3 at Mizuho

Adaptimmune Therapeutics ( ($ADAP) ) has shared an update. Adaptimmune Therapeutics announced structural changes, including the resignation of two ...

Adaptimmune Therapeutics Announces Key Leadership Changes

IMUX

Press Releases

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Adaptimmune Reports Q2 2024 Financial and Business Updates

Adaptimmune to Participate in Two Bank Conferences this September

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Adaptimmune Reports Q3 2024 Financial and Business Updates

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

AFFX

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Comments

Adaptimmune Therapeutics

Adaptimmune Therapeutics (ADAP) Forecast

Adaptimmune Therapeutics (NASDAQ:ADAP) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga